Pharmacy
four prominent nonprofit health systems — Baylor, Scott & White Health, Memorial Hermann Health System, Novant Health and Providence — have banded together to form the for-profit entity Longitude Health to handle increasing access to complex drugs, care coordination within huge programs like…
The Administration for Strategic Preparedness and Response July 16 announced it will work with the Department of Commerce on an assessment of the active pharmaceutical industrial base to better understand the pharmaceutical supply chain and how it has changed since the COVID-19 pandemic.
The Centers for Medicare & Medicaid Services July 16 released its final guidance on the Medicare Prescription Payment Plan which will begin next year.
Morristown, N.J.-based Atlantic Health System will soon deploy an AI-based technology that flags polypharmacy issues.
New Walgreen's CEO Tim Wentworth said he and the board will meet in April to conduct a strategic review of Walgreens’ retail, pharmacy and health care business portfolio and to develop a road map for the future.
Ballad Health in Johnson City, Tennessee, recently completed an interesting pilot to improve communication around medication adherence. It worked with Grapefruit Health, a startup focused on addressing health care’s staffing shortage by creating a workforce solely comprising clinical students.
Amid the sound bites and substance delivered at the recent HLTH conference, health care leaders, transformers and innovators shared how they plan to reshape care delivery, partner to drive innovation and help consumers get greater access to obesity and diabetes medications along with a greater…
A new plan will transition Blue Shield of California’s drug supply management from CVS Health’s PBM to five companies — a move the payer believes will save its 4.8 million members as much as $500 million a year in drug costs or about 10% to 15% of what it spends on drugs annually.
Pharmaceutical shortages and supply chain failures can have a devastating impact on patients. The RAPID Reserve Act would establish a program to improve supply chain resiliency for critical generic drug products, ensuring adequate supply is available even in the event of a shortage.
The Pharmaceutical Supply Chain Risk Assessment Act of 2023 would require a comprehensive risk assessment of the entire U.S. pharmaceutical supply chain. This overarching project will help provide critical information necessary to mitigate and prevent drug supply shortages.